Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Sotevtamab

Monoclonal antibody · Antagonist of secreted clusterin (sCLU) (CLU) · developed by ImmunityBio

Phase 1 Most advanced trial (none active)

IBRX Developer

1 Registered trials

What is Sotevtamab?

Sotevtamab is a humanized IgG2 monoclonal antibody that binds secreted clusterin (sCLU) expressed by tumor cells. It inhibits sCLU-mediated signal transduction and epithelial-to-mesenchymal transition, reducing tumor cell migration and invasion while enhancing chemosensitivity. It is studied in pancreatic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Targets: secreted clusterin (sCLU) (CLU)
Mechanism: Antagonist of secreted clusterin (sCLU) (CLU)
Pathways: epithelial-to-mesenchymal transition (EMT), signal transduction
Therapy area: Oncology
Developer: ImmunityBio, Inc. (IBRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: YQ3YJK67AF

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07488884	Phase 1	Pancreatic Cancer Resectable	Withdrawn	IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic CancerPancreatic Cancer Resectable

Other drugs acting on CLU

Custirsen Phase 3

More from ImmunityBio

Nogapendekin Alfa Inbakicept FDA approved 5Fluorouracil Phase 2 AAHI-SC2 Phase 1/2 AAHI-SC3 Phase 1/2 Adenoviral Vector Ad5-CEA Vaccine Phase 1/2 agenT-797 Phase 3 Aldoxorubicin Phase 2 CD19 t-haNK Phase 2 ETBX-021 Phase 1/2 ETBX-051 Phase 1/2 ETBX-061 Phase 1/2 ETBX-071 Phase 2

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.

Follow IBRX, the company behind Sotevtamab

See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z